Fenfluramine
Also known asObedrex · Rotondin · Pesos · DL-Fenfluramine · Ponderax PA · Fenfluramina · Acino · Fenfluraminum
N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
- PubChem CID
- 3337
- ChEMBL
- CHEMBL87493
- Measurements
- 0
- InChIKey
- DBGIVFWFUFKIQN-UHFFFAOYSA-N
I · Summary
What is known
Published passages, each quoted whole and attributed to the database that published it. Two blocks are written here rather than quoted, and both say so where they stand: the synthesized summary at the top, which may draw only on the passages beneath it, and the history note, which cites the works it came from. Every claim in either carries a marker to its source.
How it acts
Dravet syndrome is a complex pediatric encephalopathy characterized by recurrent pharmacoresistant seizures of variable type, delayed development, and in many cases, impairment in speech, language, gait, and other neurocognitive functions. Despite substantial variation in presentation and severity, roughly 80% of patients with Dravet syndrome have mutations in the _SCN1A_ gene, which encodes the alpha subunit of a voltage-gated sodium channel (Nav1.1). This channel is predominantly localized in inhibitory GABAergic interneurons as well as in excitatory pyramidal neurons; it is thought that dysfunction of neurotransmission regulation results in the seizures and other corresponding symptoms of……
The exact mechanism of action of fenfluramine has not been clearly defined. Results of animal studies indicate that its appetite-inhibiting may result from stimulation of the ventromedial nucleus of the hypothalamus. The mechanism by which this stimulation is mediated has not yet been determined. Although fenfluramine is used in the treatment of obesity as an anorexigenic, it has not been firmly established that the pharmacologic action is principally one of appetite suppression; other CNS actions and/or metabolic effects may be involved. ... Cardiovascular and autonomic effects produced by fenfluramine in animals appear to be qualitatively similar to those of amphetamine, but as a pressor a…
Hazardous Substances Data Bank (HSDB)McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 97. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1997 (Plus Supplements)., p. 1770
Behavior carries the pharmacological classes and the acute-effect durations, with plasma half-life kept separate from duration of effect.
History, discovery and cultural use
— Not in this archive. PubChem, ChEMBL and the Human Protein Atlas publish pharmacology, regulation and toxicology, and none of them publishes a heading for when Fenfluramine was first made, by whom, or how it has been used. That is a gap in the databases this site reads and not a gap in the literature — the history of these compounds is written, at length and under peer review, in the works below. This site does not summarize them; it says where they are. Where a published passage above happens to touch origin or traditional use, it appears inside the entry that carries it.
Histories of this field
Scholarship on psychedelics generally, not on Fenfluramine specifically. Whether any of these treats this compound is a question for the book, not for this page.
Mescaline: A Global History of the First Psychedelic
Traces mescaline and the peyote and San Pedro cacti from pre-Columbian ritual use through nineteenth-century chemistry to twentieth-century psychiatry and the counterculture.
Jay M. Mescaline: A Global History of the First Psychedelic. Yale University Press, New Haven and London; 2019. ISBN 9780300231076.
Expanding Mindscapes: A Global History of Psychedelicsopen access
Essays on the international and cross-cultural history of psychedelic science, deliberately decentring the standard North American and European account.
Dyck E, Elcock C, editors. Expanding Mindscapes: A Global History of Psychedelics. The MIT Press, Cambridge MA; 2023. ISBN 9780262546935 (paper), 9780262376891 (open access). doi:10.7551/mitpress/14417.001.0001.
Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers
Botany, ethnography and chemistry of the principal hallucinogenic plants, by the founder of modern ethnobotany and the chemist who first synthesized LSD.
Schultes RE, Hofmann A, Rätsch C. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. 2nd ed. Healing Arts Press, Rochester VT; 2001. ISBN 9780892819799.
Psychonauts: Drugs and the Making of the Modern Mind
The tradition of scientific self-experimentation with psychoactive drugs, and its part in the emergence of psychology and of modernism.
Jay M. Psychonauts: Drugs and the Making of the Modern Mind. Yale University Press, New Haven; 2023. ISBN 9780300257946.
Ancient Psychoactive Substances
Archaeological and bioarchaeological evidence for psychoactive plant use across the ancient world.
Fitzpatrick SM, editor. Ancient Psychoactive Substances. University Press of Florida, Gainesville; 2018. ISBN 9780813056708.
A chapter tracing psychedelic and entactogen research from earlier ritual use through the mid-century research period to current clinical trials.
Stroud C, Posey Norris SM, Matney C, editors. History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders. In: Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. National Academies Press, Washington DC; 2022. NBK587225.
Workshop proceedings record what participants said; they are not a consensus statement of the National Academies.
Peer-reviewed review covering the isolation, synthesis, pharmacology and ritual use of peyote and mescaline.
Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Current Molecular Pharmacology 12(3):184–194; 2019. doi:10.2174/1874467211666181010154139.
Institutional archives
- Heffter Research Institute Funds and coordinates clinical research on psilocybin, and keeps records of the studies it has supported since 1993. Sponsors the research it archives.
- Multidisciplinary Association for Psychedelic Studies (MAPS) Sponsors clinical research, chiefly on MDMA-assisted therapy, and publishes an archive of historical and contemporary documents. A sponsor and an advocacy organization, not a disinterested archive; its clinical programme has a commercial arm.
The rest of this dossier
- Toxicology — nothing published for Fenfluramine. An absent record is an absence of study, not evidence of safety.
Passages via PubChem descriptive sections, aggregating DrugBank, LiverTox, FDA, DEA, HSDB, EPA. Each is quoted whole and attributed to the database that published it. The only prose written here about Fenfluramine is the history note, which says so on its face and carries a reference for every claim in it.
II · Identity
Structure and descriptors
Descriptors are computed here with RDKit from the structure PubChem returns — not from the archive's stored copy, so an edited local structure cannot reach this table.
- Formula
- C12H16F3NR
- Molecular weight
- 231.26g/molR
- Exact mass
- 231.1235DaR
- cLogP
- 3.25R
- TPSA
- 12.0ŲR
- H-bond donors
- 1R
- H-bond acceptors
- 1R
- Rotatable bonds
- 4R
- Aromatic rings
- 1R
- Heavy atoms
- 16R
- Fraction sp³
- 0.500R
- Formal charge
- 0R
Computed with RDKit 2025.09.2 from the SMILES returned by PubChem. Audit run 26/09/2026.
Bemis–Murcko scaffold
c1ccccc1
Shared with 2-Bromomescaline, 2-TOET, 2-TOM, 2,3,4,5-Tetramethoxyamphetamine, 2,4-dimethoxyamphetamine, 2,5-Dimethoxy-4-(2-fluoroethyl)amphetamine and 129 more. All families
III · Behavior
Behavioral summary
Class, mechanism, and the duration of acute effects — each quoted from the record or trial that publishes it. Duration of effects and plasma half-life are shown separately, because they are different quantities and diverge by a factor of three or four.
Classification
Duration of acute subjective effects
—
No controlled human trial reporting a duration for this compound is cited here. The archive holds no other record of one either. A duration is not inferred from a chemical relative.
Plasma elimination half-life
How fast the body clears the drug — not how long the effects last. The two diverge sharply: LSD is cleared with a half-life of about 2.6 h while its subjective effects run 8–12 h.
Fenfluramine has an elimination half-life of 20 hours in healthy subjects.
DrugBank In one study, the mean elimination half-life of fenfluramine in patient with uncontrolled pH was about 20 hr while elimination half-life was about 11 hr when an acidic urinary pH was maintained. /Fenfluramine hydrochloride/
Hazardous Substances Data Bank (HSDB)McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 97. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1997 (Plus Supplements)., p. 1770 Considerable first-pass effect due to rapid n-dealkylation of fenfluramine is apparent after per os doses. Rapid metabolism of derivative n-(2-benzoyloxyethyl)norfenfluramine has also been reported in man with apparent biological t/2 for total drug material of about 2 hr.
Hazardous Substances Data Bank (HSDB)The Chemical Society. Foreign Compound Metabolism in Mammals Volume 3. London: The Chemical Society, 1975., p. 158 The half life of fenfluramine is 13 to 30 hours and is urine pH dependent. ...
Hazardous Substances Data Bank (HSDB)Dart, R.C. (ed). Medical Toxicology. Third Edition, Lippincott Williams & Wilkins. Philadelphia, PA. 2004., p. 875
Primary pharmacological drivers
ChEMBL holds no curated mechanism-of-action record for this compound. The measured affinities below are the evidence this archive has for what it binds.
Mechanism, as published
Quoted verbatim from the database named after each passage, never summarized.
The neurochemical mechanisms by which drugs acting on central serotoninergic system modify feeding were reviewed. Fenfluramine, a clinically effective appetite suppressant, releases serotonin from nerve terminals and inhibits its reuptake, and considerable evidence suggests that these effects mediate its anorectic activity. The D isomer o…
Hazardous Substances Data Bank (HSDB)PMID 2427023Garattini S et al; Appetite 7 Suppl: 15-38 (1986) Dravet syndrome is a complex pediatric encephalopathy characterized by recurrent pharmacoresistant seizures of variable type, delayed development, and in many cases, impairment in speech, language, gait, and other neurocognitive functions. Despite substantial variation in presentation and severity, roughly 80% of patients with Dravet synd……
DrugBank The exact mechanism of action of fenfluramine has not been clearly defined. Results of animal studies indicate that its appetite-inhibiting may result from stimulation of the ventromedial nucleus of the hypothalamus. The mechanism by which this stimulation is mediated has not yet been determined. Although fenfluramine is used in the treat…
Hazardous Substances Data Bank (HSDB)McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 97. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1997 (Plus Supplements)., p. 1770 Fenfluramine increases extracellular serotonin levels, and also acts as both a serotonergic 5-HT2 receptor agonist and σ1 receptor antagonist. These activities, through an incompletely understood mechanism, lead to anti-epileptiform activity and therapeutic benefit. This modulation has other effects such as decreased appetite, weight loss…
DrugBank
IV · Clinical
Clinical description
Where this compound's substance class sits in ICD-11 and DSM-5-TR, and how much of the recorded literature speaks to each domain of a mental status examination.
No diagnostic chapter is shown for this compound. Either PubChem records no MeSH pharmacological class for it, or the class it records is not one of the substance classes ICD-11 gives a chapter to. Inferring a chapter from the compound’s name or its binding profile would be a diagnosis this archive is in no position to make.
How much has been written about each domain
The clinical domains, and how many of the records this archive holds for this compound say something under each. What the terms mean, and the word list behind every spoke, are set out in the method.
- Mood 1
- matched on “mood” · in Pharmacology: Pharmacodynamics
- Cognition 1
- matched on “cognitiv” · in Pharmacology: Mechanism of Action
- Thought content 1
- matched on “suicid” · in Pharmacology: Pharmacodynamics
- Psychomotor activity 1
- matched on “sedat” · in Pharmacology: Pharmacodynamics
VI · Profile
Affinity rosette
No measurement for Fenfluramine converts to an affinity at a molecular target, so there is no rosette to draw. This is an absence of data, not a finding about the compound.
VII · Toxicology
Toxicological profile
What has been measured, and what has been published — kept apart, and neither scored. There is no risk rating on this page; the archive once carried one, identical for every compound, produced by a stub.
Measured in this archive
Assays that bear on toxicity, drawn from the same ChEMBL records as everything else on this page. They are measurements of what a compound binds or does to cells — not verdicts about what it does to a person.
No hERG, cytochrome, cytotoxicity or transport measurement exists for Fenfluramine in this archive.
Published toxicology
— None. The toxicology databases this site reads — HSDB, RTECS and LiverTox, by way of PubChem — hold no record for Fenfluramine. They index compounds that have been studied for decades, so most of this archive has no entry. An absent record is an absence of study, not evidence of safety.
Published passages via PubChem toxicology sections, aggregating Hazardous Substances Data Bank (HSDB), RTECS, LiverTox. No figure on this page is scored, ranked or combined into a risk level.
VIII · Evidence
Every measurement
One row per published value. The identifier in the last column resolves to the ChEMBL assay record it was read from.
No bioactivity measurement is recorded for this compound in the archive.
- P
- PubChem
- C
- ChEMBL
- R
- Computed here with RDKit
- D
- Derived here from the stored measurement
IX · Trials
Registered clinical trials
Studies filed with ClinicalTrials.gov that name this compound as an intervention. A registered trial is a protocol, not a result — status and enrollment are printed beside every row, and withdrawn studies are counted rather than hidden.
24T
Registered studies
7T
Open or ongoing
21T
With a phase recorded
By phase
A study may carry two phase codes at once, so these count studies bearing each phase and do not sum to the total.
- Phase 12
- Phase 24
- Phase 310
- Phase 44
- Not applicable1
By status
The registry’s own status for each record. Withdrawn and terminated studies are counted here rather than hidden — a stopped trial is part of what is known.
- Completed10
- Recruiting4
- Terminated3
- Unknown status2
- Approved for marketing2
- Not yet recruiting1
- Enrolling by invitation1
- Active, not recruiting1
Every matched study
Newest first by start date. Each identifier opens the registry record it came from; the title is the sponsor’s own, quoted.
- NCT07503444Recruiting · Phase 3
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
- Enrollment
- 200Testimated
- Started
- 2026-07-14
- Sponsor
- UCB BIOSCIENCES, Inc.
Conditions Rett Syndrome
Matched “Fenfluramine” in the study’s intervention “fenfluramine hydrochloride”
- NCT07651293Not yet recruiting · Not applicable
Using Fenfluramine to Test the Serotonin Deficiency Theory of Depression
- Enrollment
- 46Testimated
- Started
- 2026-07-01
- Sponsor
- Imperial College Healthcare NHS Trust
Conditions Depression - Major Depressive Disorder
Matched “Fenfluramine” in the study’s intervention “Fenfluramine Hydrochloride”
- NCT07555171Enrolling by invitation
EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment
- Enrollment
- 20Testimated
- Started
- 2026-05-01
- Sponsor
- University of Chicago
Conditions Lennox Gastaut Syndrome (LGS)
Matched “Fenfluramine” in the study’s intervention “fenfluramine HCl”
- NCT07112365Recruiting · Phase 4
The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project
- Enrollment
- 25Testimated
- Started
- 2026-04-27
- Sponsor
- The University of Texas Health Science Center, Houston
Conditions Dravet Syndrome
Matched “Fenfluramine” in the study’s intervention “Fenfluramine treatment (Fintepla)”
- NCT06679413Completed · Phase 1
A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants
- Enrollment
- 22Tactual
- Started
- 2024-12-04
- Sponsor
- UCB BIOSCIENCES, Inc.
Conditions Healthy Study Participants
Matched “Fenfluramine” in the study’s intervention “fenfluramine HCl”
- NCT06598449Recruiting · Phase 4
Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age
- Enrollment
- 5Testimated
- Started
- 2024-10-22
- Sponsor
- University of Colorado, Denver
Conditions Dravet Syndrome (DS) · Children Under 2 Years
Matched “Fenfluramine” in the study’s intervention “fenfluramine”
- NCT06118255Completed · Phase 3
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
- Enrollment
- 25Tactual
- Started
- 2024-05-21
- Sponsor
- UCB BIOSCIENCES, Inc.
Conditions Dravet Syndrome
Matched “Fenfluramine” in the study’s intervention “fenfluramine”
- NCT04289467Recruiting · Phase 2
Treatment of Refractory Infantile Spasms With Fenfluramine
- Enrollment
- 10Testimated
- Started
- 2023-06-16
- Sponsor
- Children's Hospital of Orange County
Conditions Infantile Spasm
Matched “Fenfluramine” in the study’s intervention “Fenfluramine”
- NCT05560282Terminated · Phase 3
Fenfluramine for Adult Dravet Patients
- Enrollment
- 7Tactual
- Started
- 2023-01-11
- Sponsor
- University Health Network, Toronto
Conditions Dravet Syndrome · Dravet Syndrome, Intractable
Matched “Fenfluramine” in the study’s intervention “Fenfluramine”
- NCT05232630Unknown status · Phase 4
Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes
- Enrollment
- 20Testimated
- Started
- 2022-10-20
- Sponsor
- Hospital Ruber Internacional
Conditions Refractory Epilepsy · SYNGAP1 Encephalopathy · STXBP1 Encephalopathy With Epilepsy · Inv Dup(15) Encephalopathy · Multifocal or Bilateral Malformations of Cortical Development · Continuous Spike and Waves During Slow Sleep
Matched “Fenfluramine” in the study’s intervention “Fenfluramine”
- NCT05064878Active, not recruiting · Phase 3
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
- Enrollment
- 87Tactual
- Started
- 2022-03-08
- Sponsor
- Zogenix, Inc.
Conditions CDKL5 Deficiency Disorder · Generalized Tonic Clonic Seizure · Epileptic Spasm · Refractory Seizures
Matched “Fenfluramine” in the study’s intervention “Fenfluramine”
- NCT05026398Completed · Phase 4
Fenfluramine and Cognition
- Enrollment
- 56Tactual
- Started
- 2021-04-12
- Sponsor
- University of Oxford
Conditions Cognitive Function
Matched “Fenfluramine” in the study’s intervention “Fenfluramine”
- NCT03861871Completed · Phase 2
Fenfluramine in CDKL5 Deficiency Disorder (CDD)
- Enrollment
- 7Tactual
- Started
- 2019-10-29
- Sponsor
- NYU Langone Health
Conditions CDD
Matched “Fenfluramine” in the study’s intervention “Fenfluramine Hydrochloride”
- NCT03790137Completed · Phase 3
Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).
- Enrollment
- 20Tactual
- Started
- 2019-05-31
- Sponsor
- Elizabeth Anne Thiele
Conditions Photosensitive Epilepsy
Matched “Fenfluramine” in the study’s intervention “Fenfluramine Hydrochloride”
- NCT03936777Completed · Phase 3
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
- Enrollment
- 412Tactual
- Started
- 2019-04-22
- Sponsor
- Zogenix, Inc.
Conditions Dravet Syndrome · Lennox Gastaut Syndrome · Epileptic Encephalopathy
Matched “Fenfluramine” in the study’s intervention “ZX008 (Fenfluramine Hydrochloride)”
- NCT03299842Terminated · Phase 3
A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome
- Enrollment
- 5Tactual
- Started
- 2017-07-12
- Sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Conditions Dravet Syndrome
Matched “Fenfluramine” in the study’s intervention “ZX008 (Fenfluramine Hydrochloride)”
- NCT02926898Completed · Phase 3
A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome
- Enrollment
- 87Tactual
- Started
- 2017-01-27
- Sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Conditions Dravet Syndrome
Matched “Fenfluramine” in the study’s intervention “ZX008 (Fenfluramine Hydrochloride)”
- NCT02823145Completed · Phase 3
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome
- Enrollment
- 375Tactual
- Started
- 2016-06-08
- Sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Conditions Dravet Syndrome
Matched “Fenfluramine” in the study’s intervention “ZX008 (Fenfluramine Hydrochloride)”
- NCT02682927Completed · Phase 3
A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome
- Enrollment
- 262Tactual
- Started
- 2016-01-15
- Sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Conditions Dravet Syndrome · Seizure Disorder
Matched “Fenfluramine” in the study’s intervention “ZX008 (Fenfluramine Hydrochloride)”
- NCT02655198Unknown status · Phase 2
Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy
- Enrollment
- 13Tactual
- Started
- 2016-01
- Sponsor
- KU Leuven
Conditions Epilepsy · Lennox Gastaut Syndrome
Matched “Fenfluramine” in the study’s intervention “Fenfluramine”
- NCT00000506Completed · Phase 2
Cardiovascular System in Obesity: Effect of Treatment
- Enrollment
- — no enrollment recorded in the registry entry
- Started
- 1983-05
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Conditions Heart Diseases · Obesity · Vascular Diseases
Matched “Fenfluramine” in the study’s intervention “fenfluramine”
- NCT00000313Terminated · Phase 1
Predictive Values of Serotonergic Alterations for Outcome - 2
- Enrollment
- 0Tnot qualified
- Started
- — no start date recorded
- Sponsor
- National Institute on Drug Abuse (NIDA)
Conditions Cocaine-Related Disorders
Matched “Fenfluramine” in the study’s intervention “Fenfluramine”
- NCT04437004Approved for marketing
Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)
- Enrollment
- — no enrollment recorded in the registry entry
- Started
- — no start date recorded
- Sponsor
- University of California, Los Angeles
Conditions Dravet Syndrome
Matched “Fenfluramine” in the study’s intervention “Fenfluramine”
- NCT03780127Approved for marketing
ZX008 Expanded Access Protocol
- Enrollment
- — no enrollment recorded in the registry entry
- Started
- — no start date recorded
- Sponsor
- Zogenix, Inc.
Conditions Dravet Syndrome
Matched “Fenfluramine” in the study’s intervention “Fenfluramine Hydrochloride”
Records from ClinicalTrials.gov (U.S. National Library of Medicine, NIH), API v2. A study is listed against a compound only when a verified name for that compound appears as a whole word in one of the study's own intervention names. A short code must appear as written, and a name the registry uses for something else (Aleph, a vaccine maker) is not matched. Title matches are not accepted. The matched name and the intervention text it matched are shown with every row.
Searched as Fenfluramine · DL-Fenfluramine · Ponderax PA. Run this search at the registry — it returns the unfiltered result, including studies this page rejected as belonging to a different molecule.
A registered trial is a protocol somebody filed with the registry. It is not a result, and nothing on this plate says whether Fenfluramine worked.
X · Legal
Controlled-substance status
United States federal scheduling, read from the DEA records this archive holds. Not legal advice, and an absent record is not a finding that a compound is uncontrolled.
An absent DEA record is not a finding that Fenfluramine is legal. It means this archive holds no DEA passage for it. The Controlled Substances Analogue Enforcement Act reaches substances that appear on no schedule by name, and many compounds here are ring-substituted analogues of scheduled drugs. Nothing on this plate should be read as saying a compound may lawfully be made, held or supplied.
United States federal status only. State law differs, and so does the law of every other country — none of it is represented here. Scheduling changes, and this reflects the DEA records held by PubChem descriptive sections when the monograph was last harvested, not necessarily today. This is a record of what a database publishes, not legal advice.
XI · Literature
Sources behind this dossier
The papers this compound's values were read from, ranked by what each contributed. Not a review of the field.
Every paper below is one some value on this page came from — a binding constant, a passage of pharmacology or toxicology, or a measured duration. Each entry says what this archive took from it. Nothing else is claimed about any of them: the title is the study’s own account of itself, and a summary written here would be an assertion with no source behind it.
- 01
Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system
Garattini S, Mennini T, Bendotti C et al. · Appetite 1986
- · Mechanism of Action